Discovery of PF-07220060, a potent and selective CDK4 inhibitor

被引：1
|
作者：
Anders, Lars
Gallego, Gary
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-ND12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ND12
引用
收藏
页数：2
相关论文
共 50 条
  • [41] PALBOCICLIB Cyclin CDK4/CDK6 Inhibitor Oncolytic
    Haddley, K.
    DRUGS OF THE FUTURE, 2013, 38 (11) : 745 - 755
  • [42] The identification of combinations for the CDK4 and CDK6 inhibitor, abemaciclib
    Gong Xueqian
    Chio, Li-Chun
    Webster, Yue
    Lallena, Maria Jose
    Boehnke, Karsten
    Torres, Raquel
    Iversen, Phil
    De Dios, Alfonso
    Smith, Ian
    Reinhard, Christoph
    Peng, Sheng-Bin
    Dempsey, Jack
    Burke, Teresa
    Chen, Shih-Hsun
    Stewart, Trent
    Beckmann, Richard
    Wu, Wenjuan
    Buchanan, Sean G.
    MOLECULAR CANCER RESEARCH, 2016, 14
  • [43] Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer
    Freeman-Cook, Kevin D.
    Hoffman, Robert L.
    Behenna, Douglas C.
    Boras, Britton
    Carelli, Jordan
    Diehl, Wade
    Ferre, Rose Ann
    He, You-Ai
    Hui, Andrea
    Huang, Buwen
    Huser, Nanni
    Jones, Rhys
    Kephart, Susan E.
    Lapek, John
    McTigue, Michele
    Miller, Nichol
    Murray, Brion W.
    Nagata, Asako
    Nguyen, Lisa
    Niessen, Sherry
    Ninkovic, Sacha
    O'Doherty, Inish
    Ornelas, Martha A.
    Solowiej, James
    Sutton, Scott C.
    Tran, Khanh
    Tseng, Elaine
    Visswanathan, Ravi
    Xu, Meirong
    Zehnder, Luke
    Zhang, Qin
    Zhang, Cathy
    Dann, Stephen
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (13) : 9056 - 9077
  • [44] Discovery of CDK4 inhibitors by convolutional neural networks
    Xu, Yinqiu
    Chen, Pingping
    Lin, Xinhao
    Yao, Hequan
    Lin, Kejiang
    FUTURE MEDICINAL CHEMISTRY, 2019, 11 (03) : 165 - 177
  • [45] The CDK4/6 inhibitor has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma
    Ku, Bo Mi
    Koh, Jiae
    Bae, Yeon-Hee
    Sun, Jong-Mu
    Lee, Se-hoon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    CANCER RESEARCH, 2016, 76
  • [46] Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs
    Green, Jennifer L.
    Okerberg, Eric S.
    Sejd, Josilyn
    Palafox, Marta
    Monserrat, Laia
    Alemayehu, Senait
    Wu, Jiangyue
    Sykes, Maria
    Aban, Arwin
    Serra, Violeta
    Nomanbhoy, Tyzoon
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (04) : 771 - 779
  • [47] Discovery of a Potent Glutathione Peroxidase 4 Inhibitor as a Selective Ferroptosis Inducer
    Xu, Congjun
    Xiao, Zhanghong
    Wang, Jing
    Lai, Hualu
    Zhang, Tao
    Guan, Zilin
    Xia, Meng
    Chen, Meixu
    Ren, Lingling
    He, Yuanfeng
    Gao, Yuqi
    Zhao, Chunshun
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (18) : 13312 - 13326
  • [48] Astex shapes CDK4/6 inhibitor for approval
    Peplow, Mark
    NATURE BIOTECHNOLOGY, 2017, 35 (05) : 395 - 396
  • [49] Oral CDK4/6 inhibitor in clinical trials
    Bennet, Neil
    LANCET ONCOLOGY, 2012, 13 (03): : E91 - E91
  • [50] Improving immunotherapy with a combination of CDK4/6 inhibitor
    Yoshida, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S208 - S208
12345